Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
After being spurned at the FDA, PTC buys a controversial Duchenne MD therapy from Marathon
Endpoints
Thu, 03/16/17 - 09:48 am
FDA
PTC Therapeutics
Duchenne Muscular Dystrophy
Emflaza
Marathon Pharma
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
Sat, 03/11/17 - 11:59 am
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
Mon, 02/27/17 - 09:15 am
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD
Endpoints
Mon, 02/27/17 - 09:13 am
Duchenne Muscular Dystrophy
R&D
CRISPR-Cas9
Exonics Therapeutics
Marathon halts launch of DMD drug as $89K price attracts congressional heat
Fierce Pharma
Tue, 02/14/17 - 12:12 pm
Marathon Pharma
Duchenne Muscular Dystrophy
drug pricing
Bernie Sanders
Emflaza
The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price
Endpoints
Mon, 02/13/17 - 10:00 am
Marathon Pharma
R&D
Duchenne Muscular Dystrophy
Emflaza
Why Did That Drug Price Increase 6,000%? It's The Law
Forbes
Sat, 02/11/17 - 12:40 pm
drug pricing
deflazacort
generics
Duchenne Muscular Dystrophy
Emflaza
Marathon Pharma
FDA approves Marathon Pharma's Duchenne muscular dystrophy drug
Marketwatch
Thu, 02/9/17 - 09:29 pm
FDA
Marathon Pharma
Duchenne Muscular Dystrophy
Emflaza
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Thu, 01/19/17 - 11:47 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Wed, 01/11/17 - 09:57 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
Fri, 12/23/16 - 10:01 am
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Wed, 12/21/16 - 10:52 am
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Thu, 12/15/16 - 10:05 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
Medicaid
payers
insurers
Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
Endpoints
Wed, 12/14/16 - 09:18 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
Bizjournals.com
Sun, 11/13/16 - 11:56 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
eteplirsen
FDA emails show how upset some officials were over the Sarepta approval
Stat/Pharmalot
Sat, 11/5/16 - 01:25 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
FDA official warns other drug makers not to copy Sarepta
Stat/Pharmalot
Thu, 10/20/16 - 08:16 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
PTC shares plunge anew after FDA slaps down Duchenne drug for a second time
Endpoints
Mon, 10/17/16 - 11:46 pm
PTC Therapeutics
FDA
Duchenne Muscular Dystrophy
Translarna
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Mon, 10/17/16 - 11:41 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
Biomarin
Anthem
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
Thu, 10/13/16 - 03:33 pm
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
Pages
« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »